Merck & Co., Inc. (TSX:MRK)
32.75
+0.13 (0.40%)
Nov 13, 2026, 4:00 PM EST
Merck & Co. Revenue
Merck & Co. had revenue of $18.09B USD in the quarter ending September 30, 2026, with 4.68% growth. This brings the company's total for the last twelve months to $67.38B, up 4.89% year-over-year. In the year 2025, Merck & Co. had annual revenue of $65.01B with 1.31% growth.
Revenue (ttm)
$67.38B
Revenue Growth
+4.89%
P/S Ratio
5.43
Revenue / Employee
$898.37K
Employees
75,000
Market Cap
519.14B CAD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Merck & Co. breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.01B | 843.00M | 1.31% |
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | -5.32B | -11.36% |
| Dec 31, 2019 | 46.84B | 4.55B | 10.75% |
| Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
| Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
| Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
| Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
| Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
| Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
| Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
| Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
| Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
| Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
| Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
| Dec 31, 2007 | 24.20B | 13.60B | 128.41% |
| Dec 31, 2006 | 10.59B | 1.09B | 11.42% |
| Dec 31, 2005 | 9.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.21B |
| Extendicare | 2.17B |
| Curaleaf Holdings | 1.92B |
| Green Thumb Industries | 1.76B |
| WELL Health Technologies | 1.56B |
| Sienna Senior Living | 1.08B |
| Vireo Growth | 611.54M |
| Knight Therapeutics | 563.45M |
Merck & Co. News
- 3 days ago - Merck announces European CHMP recommends approval of Enflonsia - TheFly
- 3 days ago - Merck announces European CHMP recommends approval of Enflonsia - TheFly
- 3 days ago - Merck reports European CHMP recommends approval of Welireg - TheFly
- 3 days ago - Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season - Business Wire
- 3 days ago - Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy - Business Wire
- 4 days ago - The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment - Market Watch
- 4 days ago - Surrozen price target raised to $80 from $42 at Guggenheim - TheFly
- 4 days ago - Merck to Participate in the Jefferies Global Healthcare Conference in London - Business Wire